Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Prince, H Miles, Kim, Youn H, Horwitz, Steven M, Dummer, Reinhard, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, GeLangue:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31266-7
Date:
June, 2017
Fichier:
PDF, 627 KB
english, 2017